<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762500</url>
  </required_header>
  <id_info>
    <org_study_id>LYC-30937-2001</org_study_id>
    <secondary_id>2016-000518-31</secondary_id>
    <nct_id>NCT02762500</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lycera Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lycera Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally
      once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score
      (TMS) of 4-11 inclusive, with an endoscopic score of ≥ 2 and a rectal bleeding score of ≥ 1
      at screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 120 subjects will be randomized to receive either enteric-coated LYC-30937-EC
      25 mg PO QD or matching placebo PO QD for the duration of 8 weeks. Randomization will be
      stratified based on previous exposure to anti-TNF agents such that at least 50% of the
      randomized subjects will be anti-TNF naïve .

      The study will consist of 3 phases:

        -  screening phase: up to 4 weeks

        -  double-blind placebo-controlled phase treatment: 8 weeks

        -  post-treatment follow-up: 2 weeks

      Eligible subjects will be randomized at Week 0 (Study Day 1) to either LYC-30937-EC 25 mg or
      placebo. Screening will occur from Study Days -28 to -1. Randomization and first dosing will
      occur at Week 0/Study Day 1. Double-blind study visits will occur at Weeks 2, 4, and 8, with
      the last dose at Week 8/Study Day 57. Subjects will return at Week 10 for a post-treatment
      safety follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve clinical remission at Week 8 using modified Mayo score (MMS). Clinical remission is defined as Mayo stool frequency score of ≤1, a Mayo rectal bleeding score of 0 and Mayo endoscopy score of ≤ 1.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve clinical remission at Week 8 using the total Mayo score (TMS). Clinical remission is defined as Mayo score of ≤ 2, with no individual score &gt;1.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a clinical response at Week 8, defined as a reduction from baseline MMS of ≥ 2 points and ≥ 25%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a clinical response at Week 8, defined as a reduction from baseline TMS of ≥ 3 points and ≥ 30%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 8 in fecal calprotectin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and type of adverse events (AEs) serious adverse events (SAEs) and AEs that led to discontinuation of treatment.</measure>
    <time_frame>10 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>LYC-30937-EC 25 mg PO QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYC-30937-EC 25 mg by mouth once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PO QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo by mouth once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYC-30937-EC</intervention_name>
    <arm_group_label>LYC-30937-EC 25 mg PO QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo PO QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical UC diagnosis ≥ 6 months prior to screening with minimum disease extent of ≥
             15cm from anal verge.

          -  Active UC defined as a TMS of 4-11 (inclusive) with endoscopic subscore of ≥ 2 and
             rectal bleeding subscore of ≥ 1 at screening.

          -  Females of childbearing potential must have a negative pregnancy test at screening and
             baseline visits and must agree to use acceptable methods of birth control while in the
             trial and for 30 days after taking the last dose of study drug.

          -  May be currently receiving treatment with oral aminosalicylates (ASA) for ≥ 6 weeks at
             a stable dose for ≥ 3 weeks prior to the screening screening endoscopy and/or
             thiopurine at a stable dose ≥ 8 weeks prior to the screening endoscopy and/or
             prednisone (dose 20 mg daily) or equivalent for ≥ 4 weeks and receiving stable dose
             for ≥ 2 weeks prior to screening endoscopy

          -  able to provide written informed consent and be compliant with study procedures.

        Exclusion Criteria:

          -  History of Crohn's disease (CD) or indeterminate colitis or the presence or history of
             fistula consistent with CD.

          -  Presence of colon polyps.

          -  Severe extensive disease that in the investigators discretion is likely to require
             colonic surgery during the 8 week double-blind portion of the trial (eg, fulminant
             colitis, toxic megacolon, bowel perforation, evidence of acute abdomen).

          -  History of alcohol or drug abuse within 1 year of randomization.

          -  History of cancer including solid tumors and hematological malignancies (except basal
             cell and in situ squamous cell carcinomas of the skin that have been adequately
             treated with no recurrence for ≥ 1 year prior to screening.

          -  History or currently active primary or secondary immunodeficiency.

          -  Clinically relevant hepatic, neurologic, pulmonary, ophthalmological,
             gastrointestinal, endocrine, psychiatric, or other major systemic disease making
             implementation of the study difficult or that would put the subject at risk by
             participating in the study

          -  Positive test for Clostridium difficile or positive stool culture for enteric
             pathogens or presence of ova or parasites at screening.

          -  Liver function tests &gt; 1.5 x upper limit of normal (ULN) or direct bilirubin &gt; 1.5 x
             ULN

          -  Hemoglobin &lt; 8.5 g/dl

          -  Neutrophils &lt; 1500/mm3

          -  White blood cell (WBC) count &lt; 3000/mm3

          -  Platelets &lt; 80000 mm3

          -  International normalized ratio (INR) &gt; 1.5

          -  Treatment with an immunosuppressant agent within 8 weeks of screening.

          -  Previous exposure to ≥ 2 approved or investigational biologic agents to treat UC.

          -  History of UC treatment with a biologic agent within 12 weeks of screening.

          -  Treatment with rectal steroids within 2 weeks of screening.

          -  Treatment with an investigational agent within 30 days of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Jeffrey Wilkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lycera Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Flourtown</city>
        <state>Pennsylvania</state>
        <zip>19031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Union City</city>
        <state>Tennessee</state>
        <zip>38261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Sites</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-659</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Kielce</city>
        <zip>25 364</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-415</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-009</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Ksawerów</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-008</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Nowa Sól</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Staszów</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Wloclawek</city>
        <zip>87-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-053</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>54-144</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-449</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Łódź</city>
        <zip>93-034</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Niš</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Subotica</city>
        <zip>24000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Zrenjanin</city>
        <zip>23000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

